Key factors
sym | ARCT |
exch | US |
MCap | 708.40M |
Beta | 2.601 |
EPS | -1.12 |
Div date | 0000-00-00 |
Yesterday
sym | ARCT |
exch | US |
close | 26.17 |
50 Day MA | 35.27 |
200 Day MA | 30.01 |
52 Week High | 43.81 |
52 Week Low | 17.52 |
Target Price | 67.63 |
Market Cap Mln | 708.40 |
Share statistics
Shares Outstanding | 26.91M |
Shares Float | 24.55M |
Percent Institutions | 92.17 |
PercentInsiders | 8.748 |
SharesShort | 4810.06K |
Short Ratio | 8.56 |
Shares Short Prior Month | 4205.89K |
Short Percent | 23.80 |
Income
Revenue TTM | 166.79M |
Revenue Per Share TTM | 6.264 |
Quarterly Revenue Growth YOY | -80.8 |
Gross Profit TTM | 62.94M |
EBITDA | -75.2M |
Diluted Eps TTM | -1.12 |
earning
Operating Margin TTM | -0.59 |
EPS Estimate Current Quarter | -0.99 |
EPS Estimate Current Year | -2.35 |
EPS Estimate Next Quarter | -1.06 |
EPS Estimate Next Year | 0.6 |
Earnings Share | -1.12 |
Dividend
Dividend Date | 2017-11-16 |
Last Split Date | 2017-11-16 |
Last Split Factor | 1:7 |
business
Enterprise Value Ebitda | -23.1 |
Enterprise Value Revenue | 3.541 |
Book Value /share | 10.38 |
Price Book MRQ | 2.945 |
Price Sales TTM | 4.910 |
ProfitMargin | -0.17 |
ReturnOnAssetsTTM | -0.11 |
ReturnOnEquityTTM | -0.10 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US03969T1097 |
CIK | 1768224 |
Code | ARCT |
CUSIP | 03969T109 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-18 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 2.477 |
Full Time Employees | 180.0 |
IPODate | 2020-04-16 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Arcturus Therapeutics Holdings Inc |
Address | 10628 Science Center Drive, San Diego, CA, United States, 92121 |
Country Name | USA |
Phone | 858 900 2660 |
Web URL | https://arcturusrx.com |
Logo URL | /img/logos/US/ARCT.png |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.